Tags

Type your tag names separated by a space and hit enter

Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
Neurobiol Aging 2012; 33(10):2272-81NA

Abstract

Our aim was to identify the best diagnostic test sequence for predicting Alzheimer's disease (AD)-type dementia in subjects with mild cognitive impairment (MCI) using cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers. We selected 153 subjects with mild cognitive impairment from a multicenter memory clinic-based cohort. We tested the CSF beta amyloid (Aβ)1-42/tau ratio using enzyme-linked immunosorbent assay (ELISA) and hippocampal volumes (HCVs) using the atlas-based learning embeddings for atlas propagation (LEAP) method. Outcome measure was progression to AD-type dementia in 2 years. At follow-up, 48 (31%) subjects converted to AD-type dementia. In multivariable analyses, CSF Aβ1-42/tau and HCV predicted AD-type dementia regardless of apolipoprotein E (APOE) genotype and cognitive scores. Test sequence analyses showed that CSF Aβ1-42/tau increased predictive accuracy in subjects with normal HCV (p < 0.001) and abnormal HCV (p = 0.025). HCV increased predictive accuracy only in subjects with normal CSF Aβ1-42/tau (p = 0.014). Slope analyses for annual cognitive decline yielded similar results. For selection of subjects for a prodromal AD trial, the best balance between sample size and number of subjects needed to screen was obtained with CSF markers. These results provide further support for the use of CSF and magnetic resonance imaging biomarkers to identify prodromal AD.

Authors+Show Affiliations

Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, The Netherlands. s.vos@maastrichtuniversity.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22264648

Citation

Vos, Stephanie, et al. "Test Sequence of CSF and MRI Biomarkers for Prediction of AD in Subjects With MCI." Neurobiology of Aging, vol. 33, no. 10, 2012, pp. 2272-81.
Vos S, van Rossum I, Burns L, et al. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging. 2012;33(10):2272-81.
Vos, S., van Rossum, I., Burns, L., Knol, D., Scheltens, P., Soininen, H., ... Visser, P. J. (2012). Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 33(10), pp. 2272-81. doi:10.1016/j.neurobiolaging.2011.12.017.
Vos S, et al. Test Sequence of CSF and MRI Biomarkers for Prediction of AD in Subjects With MCI. Neurobiol Aging. 2012;33(10):2272-81. PubMed PMID: 22264648.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. AU - Vos,Stephanie, AU - van Rossum,Ineke, AU - Burns,Leah, AU - Knol,Dirk, AU - Scheltens,Philip, AU - Soininen,Hilkka, AU - Wahlund,Lars-Olof, AU - Hampel,Harald, AU - Tsolaki,Magda, AU - Minthon,Lennart, AU - Handels,Ron, AU - L'Italien,Gilbert, AU - van der Flier,Wiesje, AU - Aalten,Pauline, AU - Teunissen,Charlotte, AU - Barkhof,Frederik, AU - Blennow,Kaj, AU - Wolz,Robin, AU - Rueckert,Daniel, AU - Verhey,Frans, AU - Visser,Pieter Jelle, Y1 - 2012/01/20/ PY - 2011/05/24/received PY - 2011/11/25/revised PY - 2011/12/13/accepted PY - 2012/1/24/entrez PY - 2012/1/24/pubmed PY - 2013/1/23/medline SP - 2272 EP - 81 JF - Neurobiology of aging JO - Neurobiol. Aging VL - 33 IS - 10 N2 - Our aim was to identify the best diagnostic test sequence for predicting Alzheimer's disease (AD)-type dementia in subjects with mild cognitive impairment (MCI) using cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI) biomarkers. We selected 153 subjects with mild cognitive impairment from a multicenter memory clinic-based cohort. We tested the CSF beta amyloid (Aβ)1-42/tau ratio using enzyme-linked immunosorbent assay (ELISA) and hippocampal volumes (HCVs) using the atlas-based learning embeddings for atlas propagation (LEAP) method. Outcome measure was progression to AD-type dementia in 2 years. At follow-up, 48 (31%) subjects converted to AD-type dementia. In multivariable analyses, CSF Aβ1-42/tau and HCV predicted AD-type dementia regardless of apolipoprotein E (APOE) genotype and cognitive scores. Test sequence analyses showed that CSF Aβ1-42/tau increased predictive accuracy in subjects with normal HCV (p < 0.001) and abnormal HCV (p = 0.025). HCV increased predictive accuracy only in subjects with normal CSF Aβ1-42/tau (p = 0.014). Slope analyses for annual cognitive decline yielded similar results. For selection of subjects for a prodromal AD trial, the best balance between sample size and number of subjects needed to screen was obtained with CSF markers. These results provide further support for the use of CSF and magnetic resonance imaging biomarkers to identify prodromal AD. SN - 1558-1497 UR - https://www.unboundmedicine.com/medline/citation/22264648/Test_sequence_of_CSF_and_MRI_biomarkers_for_prediction_of_AD_in_subjects_with_MCI_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0197-4580(11)00549-5 DB - PRIME DP - Unbound Medicine ER -